Science Explorer Back to mapMap
Discussion
Company · Freiburg im Breisgau · Germany

Dr Falk Pharma (Germany)

drfalkpharma.deROR OpenAlex
Research works
48
▲ 178% vs 2018-21
Citations
1.2k
25.4 per fractional work
Top-10% rate
12.8%
all institutions 10.0%
Open access
50%
world 40%
International
46%
world 18%
Dr Falk Pharma (Germany)

Not ranked overall: Dr Falk Pharma (Germany) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Dr Falk Pharma (Germany) work in?

In all years, 72% of research at Dr Falk Pharma (Germany) is in Health Sciences, 23% in Life Sciences. Its largest fields are Medicine (69%), Biochemistry, Genetics and Molecular Biology (14%), Immunology and Microbiology (3%). It does 2.6× the world's share of Health Sciences.

Health Sciences: 34 fractional works · 71.6% of its workMedicine: 33 fractional works · 69.2% of its workSurgery: 7 fractional works · 14.0% of its workEpidemiology: 5 fractional works · 11.3% of its workHepatology: 4 fractional works · 7.6% of its workOncology: 4 fractional works · 7.5% of its workGastroenterology: 2 fractional works · 4.7% of its workPulmonary and Respiratory Medicine: 2 fractional works · 4.1% of its workOphthalmology: 1 fractional works · 2.9% of its workRheumatology: 1 fractional works · 2.7% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 2.5% of its workPathology and Forensic Medicine: 1 fractional works · 1.9% of its workInfectious Diseases: 1 fractional works · 1.5% of its workPsychiatry and Mental health: 1 fractional works · 1.3% of its workHematology: 1 fractional works · 1.3% of its workPharmacology: 1 fractional works · 1.2% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 0.7% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 0.7% of its workReproductive Medicine: 0 fractional works · 0.7% of its workImmunology and Allergy: 0 fractional works · 0.6% of its workGenetics: 0 fractional works · 0.6% of its workDermatology: 0 fractional works · 0.4% of its workPhysiology: 0 fractional works · 0.3% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.7% of its workNursing: 1 fractional works · 1.1% of its workNutrition and Dietetics: 1 fractional works · 1.1% of its workHealth Professions: 0 fractional works · 1.0% of its workGeneral Health Professions: 0 fractional works · 0.4% of its workEmergency Medical Services: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.4% of its workVeterinary: 0 fractional works · 0.4% of its workSmall Animals: 0 fractional works · 0.4% of its workLife Sciences: 11 fractional works · 22.6% of its workBiochemistry, Genetics and Molecular Biology: 7 fractional works · 14.1% of its workGenetics: 4 fractional works · 7.4% of its workMolecular Biology: 3 fractional works · 5.8% of its workCancer Research: 0 fractional works · 0.4% of its workEndocrinology: 0 fractional works · 0.3% of its workBiotechnology: 0 fractional works · 0.2% of its workImmunology and Microbiology: 1 fractional works · 2.7% of its workImmunology: 1 fractional works · 2.4% of its workParasitology: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workAgricultural and Biological Sciences: 1 fractional works · 2.6% of its workPlant Science: 0 fractional works · 1.0% of its workFood Science: 0 fractional works · 0.8% of its workEcology, Evolution, Behavior and Systematics: 0 fractional works · 0.7% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 2.4% of its workPharmacology: 1 fractional works · 1.5% of its workPharmaceutical Science: 0 fractional works · 0.9% of its workNeuroscience: 0 fractional works · 0.8% of its workNeurology: 0 fractional works · 0.8% of its workSocial Sciences: 2 fractional works · 3.3% of its workEconomics, Econometrics and Finance: 1 fractional works · 2.6% of its workEconomics and Econometrics: 1 fractional works · 2.6% of its workPsychology: 0 fractional works · 0.7% of its workClinical Psychology: 0 fractional works · 0.4% of its workSocial Psychology: 0 fractional works · 0.4% of its workPhysical Sciences: 1 fractional works · 2.4% of its workChemistry: 1 fractional works · 1.1% of its workOrganic Chemistry: 1 fractional works · 1.1% of its workEngineering: 0 fractional works · 0.8% of its workBiomedical Engineering: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.4% of its workEnvironmental Science: 0 fractional works · 0.4% of its workEcology: 0 fractional works · 0.4% of its workMathematics: 0 fractional works · 0.2% of its workComputer Science: 0 fractional works · 0.1% of its workALL ITS WORKDr Falk Pharma(Germany)48fractional works, all years
Life Sciences23%Physical Sciences2%Health Sciences72%Social Sciences3%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 16 fields, with their numbers
    1. Medicine3369.2%
    2. Nursing11.1%
    3. Health Professions01.0%
    4. Veterinary00.4%
    1. Biochemistry, Genetics and Molecular Biology714.1%
    2. Immunology and Microbiology12.7%
    3. Agricultural and Biological Sciences12.6%
    4. Pharmacology, Toxicology and Pharmaceutics12.4%
    5. Neuroscience00.8%
    1. Economics, Econometrics and Finance12.6%
    2. Psychology00.7%
    1. Chemistry11.1%
    2. Engineering00.8%
    3. Environmental Science00.4%
    4. Mathematics00.2%
    5. Computer Science00.1%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.39× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 2.37× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 3.02× its world share, 0 worksImmunology and Micro…Chemistry: 0.11× its world share, 0 worksChemistryComputer Science: 0.02× its world share, 0 worksComputer ScienceEngineering: 0.08× its world share, 0 worksEngineeringHealth Professions: 0.70× its world share, 0 worksHealth ProfessionsMedicine: 3.86× its world share, 7 worksMedicineNursing: 5.49× its world share, 0 worksNursingEconomics, Econometrics and Finance: 0.11× its world share, 0 worksEconomics, Econometr…Psychology: 0.60× its world share, 0 worksPsychology1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Nursing, 5.5×. Every wedge is a field page.

All 11 fields, with their numbers
  1. Nursing5.49×0 works
  2. Medicine3.86×7 works
  3. Immunology and Microbiology3.02×0 works
  4. Biochemistry, Genetics and Molecular Biology2.37×1 works
  5. Health Professions0.70×0 works
  6. Psychology0.60×0 works
  7. Agricultural and Biological Sciences0.39×0 works
  8. Chemistry0.11×0 works
  9. Economics, Econometrics and Finance0.11×0 works
  10. Engineering0.08×0 works
  11. Computer Science0.02×0 works

Who are the top researchers at Dr Falk Pharma (Germany)?

Ranked on the quality score, Ralph Müeller, Roland Greinwald and Karin Dilger lead among researchers whose main affiliation is Dr Falk Pharma (Germany).

  1. 1 Ralph Müeller Germany · #687,001 worldwide 2.3k citations · 67 works
  2. 2 Roland Greinwald Germany · #810,137 worldwide 4.6k citations · 168 works
  3. 3 Karin Dilger Germany · #1,448,569 worldwide 1.9k citations · 41 works
  4. 4 Ralf Mohrbacher Germany · #1,554,040 worldwide 951 citations · 62 works
  5. 5 K. Dilger Germany · #2,135,249 worldwide 678 citations · 16 works
  6. 6 Bernhard Tewes Germany · #2,356,398 worldwide 257 citations · 27 works
  7. 7 Tanju Nacak Germany · #3,222,897 worldwide 184 citations · 21 works
All ranked researchers at Dr Falk Pharma (Germany)

What are the most cited papers from Dr Falk Pharma (Germany)?

The most cited paper from Dr Falk Pharma (Germany) is "Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune Hepatitis" (Michael Peter Manns, Marek Woynarowski, Wolfgang Kreisel et al., 2010), with 447 citations. Next come "Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial" (306) and "norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis" (295).

Most cited papers
#PaperReleasedCitations
1 Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune Hepatitis Michael Peter Manns, Marek Woynarowski, Wolfgang Kreisel et al. · Gastroenterology Open access 23 Jun 2010 447
2 Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial Alfredo José Lucendo et al. · Gastroenterology Open access 26 Mar 2019 306
3 norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis Peter Fickert, Gideon Morris Hirschfield, Gerald Denk et al. · Journal of Hepatology Open access 18 May 2017 295
4 A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease Detlef Schuppan et al. · New England Journal of Medicine Open access 30 Jun 2021 237
5 Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis Alex Straumann et al. · Gastroenterology Open access 25 Jul 2020 220
All 60 most cited papers, with filters and sorting

Which keywords describe research at Dr Falk Pharma (Germany)?

By fractional works in all years, weighted toward what it does more of than the world: Epidemiology, Diagnosis, Management, Inflammatory Bowel Disease, Pathogenesis, Treatment, Guidelines and Children.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Epidemiology13▲ 6.7×24 topics
  2. Diagnosis8▲ 16×12 topics
  3. Management8▲ 21×11 topics
  4. Inflammatory Bowel Disease7▲ 129×4 topics
  5. Pathogenesis6▲ 23×5 topics
  6. Treatment5▲ 8.1×13 topics
  7. Guidelines4▲ 19×4 topics
  8. Children4▲ 33×5 topics
  9. Genetics4▲ 11×4 topics
  10. Adults4▲ 104×2 topics
  11. Immunology4▲ 64×2 topics
  12. Crohn's Disease4▲ 93×2 topics
  13. Eosinophilic Esophagitis4▲ 254×1 topic
  14. Histologic Remission4▲ 254×1 topic
  15. Therapies4▲ 210×1 topic
  16. Ulcerative Colitis4▲ 210×1 topic
  17. Inflammation3▲ 2.9×12 topics
  18. Liver Transplantation3▲ 43×4 topics
  19. Proton Pump Inhibitors3▲ 75×2 topics
  20. Epidemiological Study3▲ 73×2 topics
  21. Insulin Resistance3▲ 12×3 topics
  22. Metabolic Syndrome3▲ 6.6×4 topics
  23. Collagenous Colitis3▲ 208×1 topic
  24. Hepatic Steatosis3▲ 36×2 topics
  25. Microscopic Colitis3▲ 208×1 topic
  26. Hepatocellular Carcinoma2▲ 24×2 topics
  27. NAFLD2▲ 47×1 topic
  28. NASH2▲ 47×1 topic
  29. Immunosuppressive Therapy2▲ 26×3 topics
  30. Chemotherapy2▲ 6.7×10 topics
  31. Autoimmune Hepatitis2▲ 229×1 topic
  32. Primary Biliary Cirrhosis2▲ 229×1 topic
  33. ATP-dependent Transporters2▲ 76×1 topic
  34. Multidrug Resistance2▲ 66×1 topic
  35. Risk Factors2▲ 3.5×5 topics
  36. Intestinal Permeability2▲ 66×2 topics
  37. Prevalence2▲ 8.2×3 topics
  38. Celiac Disease1▲ 149×1 topic
  39. Genetic Variants1▲ 12×2 topics
  40. Glaucoma1▲ 16×3 topics

Which research topics does Dr Falk Pharma (Germany) publish most on?

By volume in 2022-now: Eosinophilic Esophagitis, Inflammatory Bowel Disease, Celiac Disease Research and Management and Gastric Cancer Management and Outcomes.

Eosinophilic Esophagitis3Eosinophilic Esophagitis: 3 fractional worksInflammatory Bowel Disease: 0 fractional worksCeliac Disease Research and Management: 0 fractional worksGastric Cancer Management and Outcomes: 0 fractional worksGastroesophageal reflux and treatments: 0 fractional worksEosinophilic Disorders and Syndromes: 0 fractional worksReceptor Mechanisms and Signaling: 0 fractional worksGalectins and Cancer Biology: 0 fractional worksLung Cancer Treatments and Mutations: 0 fractional worksMicrobial Metabolites in Food Biotechnology: 0 fractional works
SurgeryGeneticsGastroenterologyPulmonary and Respiratory Medicine4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Eosinophilic Esophagitis Surgery 3 works
  2. 2 Inflammatory Bowel Disease Genetics 0 works
  3. 3 Celiac Disease Research and Management Gastroenterology 0 works
  4. 4 Gastric Cancer Management and Outcomes Pulmonary and Respiratory Medicine 0 works
  5. 5 Gastroesophageal reflux and treatments Gastroenterology 0 works
  6. 6 Eosinophilic Disorders and Syndromes Rheumatology 0 works
  7. 7 Receptor Mechanisms and Signaling Molecular Biology 0 works
  8. 8 Galectins and Cancer Biology Immunology 0 works
  9. 9 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
  10. 10 Microbial Metabolites in Food Biotechnology Nutrition and Dietetics 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available49.5%not open50.5%

World: 40% of research is openly available.

with international co-authors46.2%domestic only53.8%

World: 18% is written across borders.

How has Dr Falk Pharma (Germany)'s research output changed?

Output in 2022-2025 was 178% higher than in 2018-2021.

still counting200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Dr Falk Pharma (Germany) as a percentage of every work published that year, 0.000028% in 2024.

still counting0.00020%0.00040%Dr Falk Pharma (Germany)0.000026% in 202519801990200020102020

Fractional works of Dr Falk Pharma (Germany) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Freiburg im Breisgau

All research institutions in Freiburg im Breisgau

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Dr Falk Pharma (Germany). Posts are plain text and can be reported.